JP2004508399A - 糖尿病性疾患の治療のためのリポ酸及び共役酸の組合せ - Google Patents

糖尿病性疾患の治療のためのリポ酸及び共役酸の組合せ Download PDF

Info

Publication number
JP2004508399A
JP2004508399A JP2002526363A JP2002526363A JP2004508399A JP 2004508399 A JP2004508399 A JP 2004508399A JP 2002526363 A JP2002526363 A JP 2002526363A JP 2002526363 A JP2002526363 A JP 2002526363A JP 2004508399 A JP2004508399 A JP 2004508399A
Authority
JP
Japan
Prior art keywords
formula
treatment
acid
lipoic acid
physiologically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002526363A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004508399A5 (https=
Inventor
ハッセルワンダー，オリバー
クレーマー，クラウス
バルデニウス，カイ−ウヴェ
クラット，マルティン，ヨッヘン
シュヴァイケルト，ロニィ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BASF SE
Original Assignee
BASF SE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BASF SE filed Critical BASF SE
Publication of JP2004508399A publication Critical patent/JP2004508399A/ja
Publication of JP2004508399A5 publication Critical patent/JP2004508399A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2002526363A 2000-09-12 2001-09-11 糖尿病性疾患の治療のためのリポ酸及び共役酸の組合せ Pending JP2004508399A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10045059A DE10045059A1 (de) 2000-09-12 2000-09-12 Therapeutische Kombination von Liponsäure und Konjuensäuren zur Behandlung diabetischer Störungen
PCT/EP2001/010501 WO2002022111A2 (de) 2000-09-12 2001-09-11 Kombination von liponsäure und konjuensäuren zur behandlung diabetischer störungen

Publications (2)

Publication Number Publication Date
JP2004508399A true JP2004508399A (ja) 2004-03-18
JP2004508399A5 JP2004508399A5 (https=) 2008-07-10

Family

ID=7655916

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002526363A Pending JP2004508399A (ja) 2000-09-12 2001-09-11 糖尿病性疾患の治療のためのリポ酸及び共役酸の組合せ

Country Status (10)

Country Link
US (1) US20030187058A1 (https=)
EP (1) EP1317264B1 (https=)
JP (1) JP2004508399A (https=)
CN (1) CN1216602C (https=)
AT (1) ATE271866T1 (https=)
AU (1) AU2001284057A1 (https=)
DE (2) DE10045059A1 (https=)
DK (1) DK1317264T3 (https=)
ES (1) ES2225593T3 (https=)
WO (1) WO2002022111A2 (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008031136A (ja) * 2006-07-27 2008-02-14 Bhn Kk ヒアルロン酸産生増強剤
JP2010195827A (ja) * 2010-05-12 2010-09-09 Bhn Kk 経口用老化防止剤及び美容方法
JP2016535762A (ja) * 2013-09-19 2016-11-17 ザ・リサーチ・ファウンデーション・フォー・ザ・ステイト・ユニヴァーシティ・オブ・ニューヨーク 糖尿病または肝臓脂肪症を処置する方法および物質
US10639322B2 (en) 2015-03-27 2020-05-05 The Research Foundation For The State University Of New York Methods and materials for reducing amyloid beta levels within a mammal

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050112113A1 (en) * 2000-08-16 2005-05-26 Till Jonathan S. Presbyopia treatment by lens alteration
US7935332B2 (en) * 2000-08-16 2011-05-03 Encore Health, Llc Presbyopia treatment by lens alteration
US7914815B2 (en) * 2000-08-16 2011-03-29 Encore Health, Llc Method for delivery of pharmaceuticals for treating or preventing presbyopia
US8697109B2 (en) * 2000-08-16 2014-04-15 Encore Health, Llc Caged mercaptan and seleno-mercaptan compounds and methods of using them
US8647612B2 (en) * 2008-03-05 2014-02-11 Encore Health, Llc Dithiol compounds, derivatives, and treatment of presbyopia
US8147816B2 (en) * 2000-08-16 2012-04-03 Encore Health, Llc Presbyopia treatment by lens alteration
DE602004014716D1 (de) * 2004-03-06 2008-08-14 Cognis Ip Man Gmbh Use of unsaturated fatty acids for the reduction of appetite or food intake
GB0426264D0 (en) * 2004-11-30 2004-12-29 Trigen Ltd Compounds
CN101396357B (zh) * 2007-09-29 2010-12-29 中国科学院上海生命科学研究院 硫辛酰胺在防治胰岛素抵抗中的用途
US9044439B2 (en) 2008-03-05 2015-06-02 Encore Health, Llc Low dose lipoic and pharmaceutical compositions and methods
WO2009111635A2 (en) 2008-03-05 2009-09-11 Encore Health, Llc Dithiol compounds, derivatives, and uses therefor
EP3069612A3 (en) 2009-06-15 2016-10-19 Encore Health, LLC Dithiol compounds, derivatives, and uses therefor
EP2821405B1 (en) 2009-06-15 2016-04-13 Encore Health, LLC Choline esters for treating presbyopia and cataract
CN101671331B (zh) * 2009-09-29 2011-06-01 寿光富康制药有限公司 硫辛酰维格列汀及其制备方法与应用
WO2015050809A1 (en) * 2013-10-01 2015-04-09 Novozymes A/S Processes of producing fermentation products
CA2941518A1 (en) 2014-03-03 2015-09-11 Encore Vision, Inc. Lipoic acid choline ester compositions and methods of use

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07206676A (ja) * 1993-12-21 1995-08-08 Asta Medica Ag 糖尿病の治療用薬剤
WO1999029317A1 (en) * 1997-12-12 1999-06-17 Purdue Research Foundation Methods and compositions for treating diabetes

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962030A (en) * 1997-03-07 1999-10-05 Akesis Pharmaceuticals, Inc. Dietary supplement and method of treatment for diabetic control
US6440931B1 (en) * 1999-02-23 2002-08-27 Natural Corporation Conjugated linoleic acid in treatment and prophylaxis of diabetes
US6288106B1 (en) * 1999-05-25 2001-09-11 Chronorx, Llc Processes for the synthesis and use of various α-lipoic acid complexes
AU2001234782A1 (en) * 2000-02-02 2001-08-14 Metagenics, Inc. Compositions and methods for promoting healthy joints

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07206676A (ja) * 1993-12-21 1995-08-08 Asta Medica Ag 糖尿病の治療用薬剤
WO1999029317A1 (en) * 1997-12-12 1999-06-17 Purdue Research Foundation Methods and compositions for treating diabetes

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008031136A (ja) * 2006-07-27 2008-02-14 Bhn Kk ヒアルロン酸産生増強剤
JP2010195827A (ja) * 2010-05-12 2010-09-09 Bhn Kk 経口用老化防止剤及び美容方法
JP2016535762A (ja) * 2013-09-19 2016-11-17 ザ・リサーチ・ファウンデーション・フォー・ザ・ステイト・ユニヴァーシティ・オブ・ニューヨーク 糖尿病または肝臓脂肪症を処置する方法および物質
US11160825B2 (en) 2013-09-19 2021-11-02 Research Foundation Of The State University Of New York Methods and materials for treating diabetes or liver steatosis
US10639322B2 (en) 2015-03-27 2020-05-05 The Research Foundation For The State University Of New York Methods and materials for reducing amyloid beta levels within a mammal
US11253538B2 (en) 2015-03-27 2022-02-22 The Research Foundation For The State University Of New York Methods and materials for reducing amyloid beta levels within a mammal

Also Published As

Publication number Publication date
DE10045059A1 (de) 2002-03-21
ES2225593T3 (es) 2005-03-16
ATE271866T1 (de) 2004-08-15
WO2002022111A2 (de) 2002-03-21
CN1216602C (zh) 2005-08-31
US20030187058A1 (en) 2003-10-02
WO2002022111A3 (de) 2003-02-27
AU2001284057A1 (en) 2002-03-26
DE50103029D1 (de) 2004-09-02
EP1317264A2 (de) 2003-06-11
CN1455670A (zh) 2003-11-12
DK1317264T3 (da) 2004-11-29
EP1317264B1 (de) 2004-07-28

Similar Documents

Publication Publication Date Title
JP2004508399A (ja) 糖尿病性疾患の治療のためのリポ酸及び共役酸の組合せ
US11969411B2 (en) Administration of berberine metabolites
EP3873442B1 (en) A composition for weigth loss or weight management comprising beta-hydroxybutyrate and cannabidiol
CA2229624C (en) Method of reducing bodyweight and treating obesity
JP5773870B2 (ja) ヒドロキシ酪酸エステル及びその医学的使用
CN101223999B (zh) 一种全面补充各种人体所需的营养素组合物
AU2007245501B2 (en) Use of saffron and/or safranal and/or crocin and/or picrocrocin and/or derivatives thereof as a sateity agent for treatment of obesity
JP2007501852A (ja) 体重コントロール又は減量ダイエット用のダイエット食品
WO2012141316A1 (ja) 栄養組成物
US20040265357A1 (en) Combination of liponic acid and glutamine in food and pharmaceutical products
EP3135281A1 (en) Composition for preventing or improving peripheral neuropathy
JP2024545938A (ja) ヒトにおけるｒ－ベータ－ヒドロキシブチレートおよび関連化合物の投与
US12171735B2 (en) Administration of butyrate, beta-hydroxybutyrate, cannabidiol, and related compounds in humans
CA3118317C (en) Administration of butyrate, bete-hydroxybutyrate, cannabidiol, and related compounds in humans
WO2024238879A1 (en) C5 ketone compositions and related methods for therapeutic and performance supplementation
WO2025024280A1 (en) C5 ketone compositions and related methods for treating metabolic dysfunction
JP2015145421A (ja) 体重減少および肥満処置の方法
JP2023061793A (ja) １型糖尿病の改善又は治療剤
JP2002234838A (ja) 体重減少および肥満処置の方法
JP2004339240A (ja) 体重減少および肥満処置の方法
HK1084025B (en) Sexual desire and performance enhancement with meal from plants containing protein-bound tryptophan
JP2010159304A (ja) 体重減少および肥満処置の方法
HK1084025A1 (zh) 以来自含蛋白结合型色氨酸的植物的粉增强性欲和性能力
JP2014043465A (ja) 体重減少および肥満処置の方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080513

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080513

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20111101

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120126

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120202

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120703